Journal of Diabetes Investigation (Nov 2021)

Insulin resistance limits corneal nerve regeneration in patients with type 2 diabetes undergoing intensive glycemic control

  • Georgios Ponirakis,
  • Muhammad A Abdul‐Ghani,
  • Amin Jayyousi,
  • Mahmoud A Zirie,
  • Salma Al‐Mohannadi,
  • Hamad Almuhannadi,
  • Ioannis N Petropoulos,
  • Adnan Khan,
  • Hoda Gad,
  • Osama Migahid,
  • Ayman Megahed,
  • Murtaza Qazi,
  • Fatema AlMarri,
  • Fatima Al‐Khayat,
  • Ziyad Mahfoud,
  • Ralph DeFronzo,
  • Rayaz A Malik

DOI
https://doi.org/10.1111/jdi.13582
Journal volume & issue
Vol. 12, no. 11
pp. 2002 – 2009

Abstract

Read online

Abstract Aims/Introduction This study aimed to investigate whether insulin resistance (IR) in individuals with type 2 diabetes undergoing intensive glycemic control determines the extent of improvement in neuropathy. Materials and Methods This was an exploratory substudy of an open‐label, randomized controlled trial of individuals with poorly controlled type 2 diabetes treated with exenatide and pioglitazone or insulin to achieve a glycated hemoglobin <7.0% (<53 mmol/mol). Baseline IR was defined using homeostasis model assessment of IR, and change in neuropathy was assessed using corneal confocal microscopy. Results A total of 38 individuals with type 2 diabetes aged 50.2 ± 8.5 years with (n = 25, 66%) and without (n = 13, 34%) IR were studied. There was a significant decrease in glycated hemoglobin (P < 0.0001), diastolic blood pressure (P < 0.0001), total cholesterol (P < 0.01) and low‐density lipoprotein (P = 0.05), and an increase in bodyweight (P < 0.0001) with treatment. Individuals with homeostasis model assessment of IR <1.9 showed a significant increase in corneal nerve fiber density (P ≤ 0.01), length (P ≤ 0.01) and branch density (P ≤ 0.01), whereas individuals with homeostasis model assessment of IR ≥1.9 showed no change. IR was negatively associated with change in corneal nerve fiber density after adjusting for change in bodyweight (P < 0.05). Conclusions Nerve regeneration might be limited in individuals with type 2 diabetes and IR undergoing treatment with pioglitazone plus exenatide or insulin to improve glycemic control.

Keywords